{"id":2715,"date":"2018-12-14T18:53:02","date_gmt":"2018-12-14T17:53:02","guid":{"rendered":"https:\/\/dewb.de\/en\/?p=2715"},"modified":"2019-01-25T18:53:51","modified_gmt":"2019-01-25T17:53:51","slug":"noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/","title":{"rendered":"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients"},"content":{"rendered":"<ul>\n<li><strong>Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients<\/strong><\/li>\n<li><strong>Data supports best-in-class pharmacology for NOX-A12<\/strong><\/li>\n<\/ul>\n<p><strong>Berlin, Germany, December 14, 2018, 12.30 p.m. CET<\/strong> &#8211; NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), publishes top-line efficacy data from the second part of its ongoing open label Phase I clinical trial (NCT03168139). The trial in 20 patients is testing NOX-A12 (olaptesed pegol) in combination with Merck &amp; Co.\/MSD\u2019s PD-1 inhibitor Keytruda\u00ae in metastatic, microsatellite stable pancreatic (PaC) and colorectal cancer (CRC) patients. Data will be presented at the ESMO Immuno-Oncology Congress taking place in Geneva, Switzerland, December 13-16, 2018.<br \/>Patients enrolled in the study had a mean number of 3 (PaC) or 5 (CRC) lines of prior treatment. Of the patients who were still alive after three months, as targeted in the inclusion criteria and to allow sufficient time for treatment to have an effect, 70% were still alive at 24 weeks and 50% at 36 weeks. This unexpectedly high number of patients with extended time on study relative to prior therapy and stable disease included mostly patients who progressed rapidly on their prior therapy and whose best response to prior therapy was progressive disease. Five of the patients, representing 25% in the study achieved stable disease according to the RECIST criteria used (22% PaC, 27% CRC).<\/p>\n<p><br \/>Dr. Jarl Ulf Jungnelius, CMO of NOXXON, said: \u201cNormally when patients move from one line of therapy to the next, we expect they will do less well, however what we saw repeatedly in this study was that patients who progressed very rapidly to their last therapy were able to stay on the NOX-A12\/Keytruda\u00ae combination therapy for longer \u2013 in fact, up to ten times longer. This combination appears to bend the tumor growth curve downward and could benefit patients even if they do not achieve stable disease.\u201d<\/p>\n<p><br \/>\u201cThese results are very encouraging for these two difficult to treat cancers. When we look at the results obtained with only one dose of NOX-A12 per 3-week Keytruda\u00ae cycle, we believe that NOX-A12 has best-in-class pharmacology. We believe that further studies with NOX-A12 are needed in these indications and we are currently refining the design of the next trials,\u201d said Aram Mangasarian, CEO of NOXXON.<\/p>\n<p><br \/>The study confirmed the mechanism of action of NOX-A12 in these tumor types where both proteomic and immunohistochemical analyses confirmed abundant expression of the CXCL12 chemokine drug target in both tumor types. The extent of neutralization of the target by NOX-A12 correlated with a \u201chotter\u201d immune response and clear clinical benefit for patients.<\/p>\n<p><br \/>The poster is available on the NOXXON <a href=\"https:\/\/www.noxxon.com\/downloads\/poster\/2018-Poster-ESMO-IO.pdf\">website<\/a>.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2715\" data-postid=\"2715\" class=\"themify_builder_content themify_builder_content-2715 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients<\/p>\n","protected":false},"author":3,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-14T17:53:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-25T17:53:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"marcoscheidler\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"marcoscheidler\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/\"},\"author\":{\"name\":\"marcoscheidler\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff\"},\"headline\":\"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients\",\"datePublished\":\"2018-12-14T17:53:02+00:00\",\"dateModified\":\"2019-01-25T17:53:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/\"},\"wordCount\":462,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/\",\"url\":\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/\",\"name\":\"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2018-12-14T17:53:02+00:00\",\"dateModified\":\"2019-01-25T17:53:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff\",\"name\":\"marcoscheidler\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g\",\"caption\":\"marcoscheidler\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients","og_url":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2018-12-14T17:53:02+00:00","article_modified_time":"2019-01-25T17:53:51+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png","type":"image\/png"}],"author":"marcoscheidler","twitter_card":"summary_large_image","twitter_misc":{"Written by":"marcoscheidler","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/"},"author":{"name":"marcoscheidler","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff"},"headline":"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients","datePublished":"2018-12-14T17:53:02+00:00","dateModified":"2019-01-25T17:53:51+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/"},"wordCount":462,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/","url":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/","name":"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2018-12-14T17:53:02+00:00","dateModified":"2019-01-25T17:53:51+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/noxxon-announces-key-finding-that-nox-a12-plus-keytruda-induces-an-immune-response-and-results-in-clinical-benefit-for-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON announces key finding that NOX-A12 plus KEYTRUDA\u00ae induces an immune response and results in clinical benefit for patients"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff","name":"marcoscheidler","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g","caption":"marcoscheidler"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2715"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2715"}],"version-history":[{"count":2,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2715\/revisions"}],"predecessor-version":[{"id":2717,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2715\/revisions\/2717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}